Autonomix Medical Selected for Best Innovation Competition at CRT 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) was selected for an oral presentation in the CRT 2026 Best Innovation Competition for its talk “Illuminating The Nervous System With Transvascular Precision-guided Technology.”
CEO Brad Hauser will present on March 9, 2026, 4:19–4:27 PM ET in the International Ballroom – West, highlighting the company’s transvascular, nerve-targeted technology and its clinical relevance.
Details
News Market Reaction – AMIX
On Mar 5, the day this news came out, AMIX closed 2.23% above the previous close.
Data tracked by StockTitan Argus for the Mar 5 session.
Key Figures
- Share price
- $0.4076
- Pre-news price on publication date
- Net loss
- $14.0 million
- Nine months ended Dec 31, 2025 (10-Q filed Feb 11, 2026)
- Cash balance
- $9.9 million
- As of Dec 31, 2025 (10-Q filed Feb 11, 2026)
- Operating cash use
- $9.4 million
- Cash used in operating activities, nine months ended Dec 31, 2025
- Needed financing
- $30–$36 million
- Estimated additional funding required to reach first indication commercialization
- Shelf warrant proceeds
- $7.7 million
- Potential gross proceeds if all Common Warrants exercised in cash
- PIPE gross proceeds
- $5.0 million
- November 2025 private placement raising capital
- Shares registered
- 13,504,998 shares
- Common stock registered on S-3 for warrant share resale
Historical Context
-
CEO outlined publication strategy and scientific validation push in new segment.
-
Selection to present long-term pancreatic cancer pain data at SSO 2026.
-
Final analysis on pancreatic cancer pain mitigation at SIO 2026 meeting.
-
PoC study at ASCO GI showed rapid and durable pain relief data.
-
European patent granted for precision cardiac neuromodulation platform.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
transvascular medical
peripheral nerve medical
interventional cardiovascular medicine medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
THE WOODLANDS, TX, March 05, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that its presentation titled, “Illuminating The Nervous System With Transvascular Precision-guided Technology,” has been selected for oral presentation in the Best Innovation Competition at Cardiovascular Research Technologies (CRT) 2026.
The presentation will be delivered by Chief Executive Officer, Brad Hauser, on Monday, March 9, 2026, from 4:19 PM to 4:27 PM ET in the International Ballroom – West.
The CRT Best Innovation Competition highlights transformative technologies with the potential to meaningfully impact patient care. Selection for oral presentation reflects the program’s emphasis on scientific innovation, technical differentiation and clinical relevance.
“Being selected for CRT’s Best Innovation Competition is a strong validation of our precision-guided, transvascular approach to interrogating and treating the nervous system,” commented Brad Hauser, CEO of Autonomix. “Our technology is designed to provide physicians with unprecedented insight into peripheral nerve signaling.”
CRT is one of the world’s leading educational forums for interventional cardiovascular medicine, with Top Abstract podium selections representing the highest-scoring submissions based on scientific merit, innovation and clinical relevance. For more information, please visit the conference website here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include expectations regarding the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions.
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.